** U.S.-listed shares of China-based drug maker Zai Lab Ltd
jump 3.3% to $16.55 premarket
** ZLab's partner Bristol Myers Squibb said late on Thursday that its drug KRAZATI had met the main goal in a late-stage study for non-small cell lung cancer (NSCLC) with a mutation
** Drug also met a key secondary goal of the study
** ZLAB expects to submit a New Drug Application for KRAZATI to China's National Medical Products Association for this indication as second or a later-line treatment this year
** BMY will complete a full evaluation of available data & discuss the results with health authorities
** Up to Thursday's close, ZLAB's U.S. shares down 41.4% YTD
(Reporting by Atharva Singh in Bengaluru)
((Atharva.singh@thomsonreuters.com))
Comments